Esophageal carcinoma: surgery without preoperative adjuvant chemotherapy.
Our experience with 100 consecutive patients with esophageal carcinoma treated with surgical intervention as the primary method of therapy between 1967 and 1987 was reviewed. Preoperative chemotherapy was not administered by us. Follow-up was complete for all 100 patients. Twelve percent of tumors were in the proximal third of the esophagus, 21% were in the middle third, and 67% were in the distal third. Adenocarcinoma accounted for 44% of all tumors, squamous cell for 55%, and adenosquamous for 1%. Six patients were in stage I, 14 were in stage II, and 80 were in stage III; no patient was in stage IV. Surgical procedures included 85 esophagogastrectomies with primary anastomoses, 11 with colon interposition, and 4 with Roux-en-Y small-bowel interposition. Six patients had radical laryngopharyngo-esophagectomy with gastric or colopharyngeal anastomosis. Operative mortality was 3%. The mean survival of stage I patients was 182 months; stage II patients, 25 months; and stage III patients, 18 months. Our data show that surgical resection without preoperative adjuvant chemotherapy remains the cornerstone of therapy for patients with carcinoma of the esophagus.
Division of Thoracic and Cardiovascular Surgery, Joseph B. Whitehead Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.
K A
KA
Mansour
R S
RS
Downey
D000230:Adenocarcinoma / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000714:Anastomosis, Surgical / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000601:surgery; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging